Streetbeat News

Products Services

BLDP

Ballard Power Systems has received orders for 96 hydrogen fuel cell engines from Solaris Bus & Coach. The engines will be used in Solaris' Urbino 12 hydrogen buses, which are sold in Europe.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:37 pm

OBIO

Orchestra BioMed has received FDA approval for its Investigational Device Exemption (IDE) for a U.S. pivotal study of Virtue Sirolimus AngioInfusion Balloon in patients with coronary in-stent restenosis. The study is expected to start before the end of 2023. The company has a strategic partnership with Terumo Corporation for the global application of Virtue SAB.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:36 pm

ENSC

Ensysce Biosciences (NASDAQ:ENSC) has received approval from the Investigational Review Board for the PF614-201 protocol, a study designed to confirm the time of onset for pain relief by PF614. The study is a key step towards the full Phase 3 evaluation of PF614, a chemically modified opioid product. The company believes that PF614's features, including its bioequivalence to OxyContin and reduced abuse potential, will make it a game changer for the treatment of severe pain.

Portfolio Pulse from Happy Mohamed

August 08, 2023 | 12:35 pm

AAPL

GOOG

GOOGL

NFTG

The NFT has announced that its product, Space Striker AI, has been approved by both Apple App Store and Google Play. This approval allows the product to be available for download on these platforms.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:34 pm

JAGX

Jaguar Health's subsidiary, Napo Pharmaceuticals, has received activation from the FDA for its Investigational New Drug (IND) application for Crofelemer, a treatment for Microvillus Inclusion Disease.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:32 pm

SILO

Silo Pharma has announced the advancement of the formulation development of SPC-15. The liquid nasal formulation will be used in SPC-15's protocol for anxiety, PTSD, and stress-related disorders.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:32 pm

AIM

AIM ImmunoTech Inc. has completed enrollment for its Phase 2 study of Ampligen, a potential treatment for post-COVID conditions. The study has enrolled 80 subjects who will receive either Ampligen or a placebo for 12 weeks. The company expects to complete dosing by Q4 2023 and release topline data by Q1 2024. The rapid enrollment pace underscores the urgent need for a therapeutic option to treat Long COVID with chronic fatigue-like symptoms.

Portfolio Pulse from Happy Mohamed

August 08, 2023 | 12:28 pm

BKR

Energy technology company Baker Hughes (NASDAQ:BKR) has signed a memorandum of understanding with airport management and operations company Avports to develop, implement and operate onsite microgrid solutions for the airport industry. The collaboration aims to address emissions reduction and the global industry's goal to focus on zero-emission buildings, horizontal airport infrastructure, vehicles and aircraft systems. The partnership will leverage Baker Hughes' energy technology portfolio, including hydrogen-ready turbines and heat recovery solutions, and Avports' focus on airport innovation and sustainability initiatives.

Portfolio Pulse from Happy Mohamed

August 08, 2023 | 12:26 pm

ORCL

Saudi telecom company Salam is partnering with Oracle to expedite its digital transformation. By implementing Oracle Cloud Scale Monetization and Oracle Unified Operations solutions, along with Oracle CRM Sales, Salam aims to replace its legacy systems with a modern, end-to-end stack. This will enable Salam to offer unique promotion bundles across various customer segments and accelerate time to revenue for existing and new digital services, such as 5G-enabled streaming, AR/VR gaming, and IoT-connected devices.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:25 pm

BURU

DRUG

MNPR

NUBURU has announced a contract with NASA for next-generation blue laser space technology, causing its stock (BURU) to surge by 324%. Bright Minds Biosciences (DRUG) has announced positive data from its first-in-human Phase 1 study of lead compound, BMB-101, leading to a 126% increase in its stock. Monopar Therapeutics (MNPR) reported that both patients treated in its Phase1B study experienced tumor size reductions, resulting in a 118% increase in its stock.

Portfolio Pulse from ryanfaloona@benzinga.com

August 08, 2023 | 12:24 pm